Clinical efficacy of azacytidine and venetoclax and prognostic impact of Tim-3 and galectin-9 in acute myeloid leukemia and high-risk myelodysplastic syndromes: A single-center real-life experience

Treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) is difficult in older patients with comorbidities and high-risk disease factors. Venetoclax, the first-in-class Bcl-2 inhibitor, has proven efficacy and safety in combination with azacytidine for treatment of hig...

Descripción completa

Detalles Bibliográficos
Autores principales: Giudice, Valentina, Serio, Bianca, Ferrara, Idalucia, Manzo, Paola, Gorrese, Marisa, Pepe, Rita, Bertolini, Angela, D’Alto, Francesca, Verdesca, Francesco, Langella, Maddalena, Filippelli, Amelia, Selleri, Carmine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810751/
https://www.ncbi.nlm.nih.gov/pubmed/36618908
http://dx.doi.org/10.3389/fphar.2022.1052060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810751/
https://www.ncbi.nlm.nih.gov/pubmed/36618908
http://dx.doi.org/10.3389/fphar.2022.1052060

Ejemplares similares